No profile data available.
Estrella Immunopharma, Inc. (ESLA) is a healthcare company in the blood cancer treatment drugs industry, based in EmeryVille, United States.
It reported revenue of $0 for fiscal year 2024, and net income of -$7.31 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $17.83 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2024; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
Estrella Immunopharma reported $0 in revenue for fiscal year 2024. In Q3 2025 revenue was $0.
$17.83 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Apollomics, Inc. (APLM), Lite Strategy, Inc. (LITS), Actinium Pharmaceuticals, Inc. (ATNM), Marker Therapeutics, Inc. (MRKR).